Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
Alaunos Therapeutics, Inc. (TCRT)Analyst
Former Speaker
Head of Investor Relations
Inhibikase Therapeutics, Inc. (IKT)Equibles does not estimate personal net worth.
Get an email with a short summary when Alaunos Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TCRT alertsAlex Lobo is recorded as Head of Investor Relations at Alaunos Therapeutics, Inc. (TCRT), Analyst at Former Speaker and Head of Investor Relations at Inhibikase Therapeutics, Inc. (IKT). Alex Lobo has spoken on 7 earnings calls across 2 companies, most recently for Inhibikase Therapeutics, Inc. on December 31, 2023. Those appearances were for Inhibikase Therapeutics, Inc. (IKT) and Alaunos Therapeutics, Inc. (TCRT). Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Alaunos Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Mark Iwicki (CEO and Board Member), Amit Munshi (Chairman and Board Member), Roberto Bellini (Chairman and Board Member) and 5 others.
“Good morning, and welcome to Inhibikase Therapeutics fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.”
“Good morning, and welcome to the Inhibikase Therapeutics Second Quarter 2023 Financial Results Conference Call and Audio Webcast. With me today is Dr. Milton Werner, Chief Executive Officer; Joseph Frattaroli, Chief Financial Officer.”
“With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Monday, May 15, 2023, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2023.”
“Good morning, and welcome to Inhibikase Therapeutics third quarter 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer.”
“And welcome to the Alaunos Therapeutics third quarter 2022 financial results conference call and audio webcast. Please note that today’s webcast contains slides, which are available through the audio webcasting platform.”
Former Speaker
Analyst
Source not stated
Biotechnology · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
Head of Investor Relations